Sutro Biopharma Inc. (STRO) Misses Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street rises on revived AI momentum as earnings season picks up
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts STRO Hot Sheet
Join SI Premium – FREE
Sutro Biopharma Inc. (NASDAQ: STRO) reported Q2 EPS of ($2.33), $0.13 worse than the analyst estimate of ($2.20). Revenue for the quarter came in at $9.84 million versus the consensus estimate of $11.58 million.
For earnings history and earnings-related data on Sutro Biopharma Inc. (STRO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASM International posts Q3 net income of €308.1m, raises 2027 revenue target
- FDA: Amgen Vectibix promotional video found false or misleading
- Equinix (EQIX) 3500 contracts of November 1000 puts trade
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
